Navigation Links
Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Date:8/30/2007

SAN DIEGO, Aug. 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced it has completed patient enrollment in a pivotal Phase III clinical trial to evaluate its investigational product candidate, intravenous acetaminophen (IV acetaminophen), for the treatment of acute pain following gynecologic surgery. This clinical trial is part of a comprehensive Phase III clinical development program for IV acetaminophen, which includes pivotal efficacy studies for the treatment of acute pain and fever, as well as safety and pharmacokinetic studies.

"The completion of patient enrollment in this clinical trial is an important milestone for Cadence," said Ted Schroeder, President and Chief Executive Officer of Cadence. "We believe that intravenous acetaminophen has the potential to meet a significant unmet medical need for an effective intravenous analgesic to treat acute pain and fever without the unwanted side effects associated with currently available treatments."

Cadence's pivotal trial of IV acetaminophen for the treatment of pain following gynecologic surgery, referred to as the IV APAP 301 Study, is a randomized, double-blind, placebo-controlled study in which a total of 331 subjects have been enrolled at 27 sites throughout the United States. Patients were treated with either IV acetaminophen or placebo in the 48-hour period following gynecologic surgery. The primary endpoint of the trial is analgesic efficacy, measured by reduction in pain intensity, compared to placebo.

"The IV APAP 301 Study is a critical eleme
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... announced that 12-month outcomes data from a subset analysis ... of print in the Journal of Interventional Cardiology ... company,s Genous Stent in diabetic patients, with low definite ... The study investigated the 1,236 diabetic patients from ...
... 23, 2011 NephRx Corporation today announced issuance ... peptide NX002, which currently is in preclinical development ... reported that NX002 had demonstrated significant efficacy when ...  Mucositis is a debilitating and often dose-limiting condition ...
Cached Medicine Technology:Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeich's Genous™ Stent in Diabetic Patients 2Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeich's Genous™ Stent in Diabetic Patients 3NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002 2NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002 3
(Date:4/24/2014)... one out of three survivors of critical illness, ... The Lancet Respiratory Medicine , and the majority ... mentally. , It is one of the largest ... outcomes of critical care survivors, according to lead ... and it highlights a significant public health issue, ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... from Sub-Saharan Africa, Latin America and Caribbean islands ... new research from St. Michael,s Hospital. , The ... of Obstetrics and Gynaecology , assessed the differences ... native-born women in six high-immigration countries Australia ... Valencia) and the United States (California, New Jersey ...
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
(Date:4/23/2014)... The internal surface area of the gastro-intestinal tract has ... square meters. Scientists at the Sahlgrenska Academy have used ... , "Actually, the inner surface of the gastro-intestinal tract ... says scientist Lars Fndriks. , The digestive tract, which ... through the intestines, has a length of about 5 ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... ... Mr. Ohad Goren will function as Pollogen,s CEO. Pollogen recently launched its latest technology- ... action - fat reduction. , ... Tel-Aviv, Israel (PRWEB) April 19, 2010 -- Pollogen Ltd , a ...
... ... accumulated medical records knowledge to offer a full Electronic Medical Records (EMR) data conversion ... ... in healthcare connectivity solutions, now offers a full range of EMR to EMR Data ...
... those who get something lodged in their throat die , ... young children who choke after swallowing a foreign object is ... real, the latest research indicates. , "In such cases, the ... K. Shah, a pediatric otolaryngologist with the Children,s National Medical ...
... first study of vitamin K and Non-Hodgkin lymphoma ... found that people who have higher intakes of vitamin K ... lymphoma. Non-Hodgkin Lymphoma is a cancer of the immune ... United States. At the 101st Annual Meeting ...
... SAN MARCOS, TXStudents, perceptions of their overall experience on ... accomplishments, but research has also found a solid relationship ... perceptions of quality of life. Are campus green spaces ... undergrads? A new study investigating this question revealed some ...
... screening, diagnosis , MONDAY, April 19 (HealthDay News) -- Researchers ... tests could be a sign that patients are at higher ... that in blacks, a common germ boosts the risk of ... often become cancerous. , Both studies are slated to be ...
Cached Medicine News:Health News:Pollogen Ltd. Names Ohad Goren Chief Executive Officer 2Health News:Pollogen Ltd. Names Ohad Goren Chief Executive Officer 3Health News:ELLKAY Launches Electronic Medical Records (EMR) Conversion Division to Healthcare Industry 2Health News:ELLKAY Launches Electronic Medical Records (EMR) Conversion Division to Healthcare Industry 3Health News:Fatal Choking a Real Risk Among Toddlers 2Health News:Fatal Choking a Real Risk Among Toddlers 3Health News:Vitamin K may protect against developing non-Hodgkin's lymphoma, say Mayo Clinic researchers 2Health News:Vitamin K may protect against developing non-Hodgkin's lymphoma, say Mayo Clinic researchers 3Health News:Campus green space more important for undergrads 2Health News:New Risk Factors for Colon Cancer Studied 2
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
... A revolutionary urological imaging ... benefits that translate into improved ... x 1k imaging technology physicians ... to see more anatomical detail ...
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
Medicine Products: